Chris Evert Withdraws From Wimbledon Coverage Following Third Ovarian Cancer Diagnosis

Tennis Hall of Famer Chris Evert, 71, announced her ovarian cancer has returned for a third time, necessitating immediate chemotherapy and her absence from the 2024 Wimbledon championships.

Chris Evert, the 71-year-old Tennis Hall of Famer and winner of 18 Grand Slam singles titles, confirmed on Thursday that her ovarian cancer has returned for the third time. This medical development forces the former world number one to withdraw from her scheduled broadcasting duties at the 2024 Wimbledon championships. Evert revealed that she has already undergone a surgical procedure as the primary step in her current recovery plan. The diagnosis follows a history with the disease that began in December 2021, followed by a second occurrence reported in December 2023.

Chemotherapy sessions are slated to begin within the next few weeks, a regimen that requires the ESPN analyst to step away from the public eye for several months. Evert described the nature of ovarian cancer as relentless in her official statement while maintaining a positive mindset regarding her prognosis. Her medical team initiated this latest round of treatment immediately after diagnostic tests confirmed the presence of malignant cells. Consequently, the legendary athlete will prioritize her physical health over professional commitments throughout the summer season.

Mike McQuade, ESPN executive vice president of production, released a formal communication expressing the network's full support for their long-time colleague. The sports media organization confirmed that the commentary booth at the All England Club will remain open for her eventual return. Evert has been a staple of major tennis coverage for decades, providing expert tactical analysis for global audiences. Her absence from the upcoming grass-court major marks a significant shift in the tournament's traditional broadcast lineup.

The 18-time major champion expressed profound gratitude toward her family and the medical staff overseeing her oncology care. She noted that the outpouring of support from the international tennis community has provided essential strength during this period. Evert’s career, which includes a record seven French Open titles and six U.S. Open trophies, was built on a foundation of mental toughness that she now applies to her clinical battle. She remains determined to complete her medical protocols and resume her role in the sport as soon as her condition stabilizes.

This professional hiatus is expected to last through the duration of her intensive treatment cycle. Evert emphasized her intention to reunite with fans and fellow commentators once her health permits a return to travel. The specific timeline for her recovery remains dependent on how her body responds to the upcoming chemical interventions. As she prepares for this next phase, the focus of the tennis world shifts toward her well-being and the success of her surgical recovery.

Evert’s initial 2021 diagnosis was caught at an early stage, a factor that has been critical in her ongoing management of the illness. She has frequently used her platform to advocate for genetic testing and early detection, citing her sister Jeanne Evert Dubin’s passing from the same disease in 2020 as a catalyst for her own screening. This third encounter with the malignancy underscores the persistent challenges associated with this specific form of cancer. Despite these setbacks, the former champion continues to exhibit the same resilience that saw her reach 34 Grand Slam singles finals.

The upcoming months will involve a rigorous schedule of hospital visits and recovery periods designed to eliminate the recurring cells. Evert’s transparency regarding her health journey has earned her widespread praise for raising awareness about women's health issues. While she will not be present at SW19 this year, her influence on the tournament remains through her storied history as a three-time Wimbledon singles winner. The sports world now watches for updates on her progress as she navigates this latest medical hurdle with characteristic grace.

ESPN has not yet named a direct replacement for her specific analytical segments, choosing instead to focus on supporting Evert’s privacy during her treatment. The network’s coverage will proceed with its remaining roster of experts, though the lack of Evert’s signature baseline perspective will be noted by viewers. Her commitment to returning to the airwaves serves as a goal for the latter half of the 2024 tennis calendar. For now, the priority remains the successful completion of her chemotherapy and the restoration of her physical vitality.